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ABSTRACT Symptoms of primary ciliary dyskinesia (PCD) are nonspecific and guidance on whom to
refer for testing is limited. Diagnostic tests for PCD are highly specialised, requiring expensive equipment
and experienced PCD scientists. This study aims to develop a practical clinical diagnostic tool to identify
patients requiring testing.
Patients consecutively referred for testing were studied. Information readily obtained from patient
history was correlated with diagnostic outcome. Using logistic regression, the predictive performance of
the best model was tested by receiver operating characteristic curve analyses. The model was simplified
into a practical tool (PICADAR) and externally validated in a second diagnostic centre.
Of 641 referrals with a definitive diagnostic outcome, 75 (12%) were positive. PICADAR applies to
patients with persistent wet cough and has seven predictive parameters: full-term gestation, neonatal chest
symptoms, neonatal intensive care admittance, chronic rhinitis, ear symptoms, situs inversus and congenital
cardiac defect. Sensitivity and specificity of the tool were 0.90 and 0.75 for a cut-off score of 5 points. Area
under the curve for the internally and externally validated tool was 0.91 and 0.87, respectively.
PICADAR represents a simple diagnostic clinical prediction rule with good accuracy and validity, ready
for testing in respiratory centres referring to PCD centres.
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Introduction
Primary ciliary dyskinesia (PCD) is a rare heterogeneous disorder characterised by abnormal ciliary
function and associated with abnormal ciliary ultrastructure in 70% of cases [1, 2]. Consequences of PCD
include impaired mucociliary clearance of the airway causing upper and lower respiratory tract symptoms
which usually present soon after birth. Neonatal manifestations range in severity from mild transient
tachypnoea to significant respiratory failure requiring prolonged respiratory support [3–5]. Patients
continue to have chronic, progressive symptoms of persistent wet cough and recurrent chest infections that
almost invariably lead to bronchiectasis. Upper airway problems include rhinosinusitis and recurrent otitis
media with hearing impairment [6]. Motile embryonic nodal cilia are important for left/right asymmetry;
approximately half of PCD patients exhibit situs inversus and 6–12% heterotaxic syndromes which may be
associated with complex congenital cardiac defects [7, 8]. Male Infertility is common since sperm flagella
have a similar ultrastructure to cilia; the incidence of female infertility is less clear, but can be explained by
immotile fallopian tube cilia [9].
The prevalence, burden of disease and prognosis of PCD patients is difficult to determine due to limited
representative international data. Reported prevalence varies from 1:2000 to 1:40000, reflecting true
variability as well as differences in access to diagnostic facilities [10–12]. A survey of 26 European
countries found that PCD is underdiagnosed or diagnosed late particularly in countries with low
healthcare expenditure [10]. In addition to expecting to improve respiratory prognosis [13–15], early
diagnosis facilitates appropriate management; management is different to non-PCD-related serous otitis
media, for example [16]. Diagnosis also allows genetic counselling for the family.
There is currently no “gold standard” test to diagnose PCD [17]. European guidelines recommend that PCD
should be confirmed in a specialist centre using appropriate diagnostic testing [18]. PCD diagnostic
investigations are complex, requiring expensive infrastructure, and an experienced team of clinicians, scientists
and microscopists [17, 19, 20]. Various models exist to deliver diagnostic services for this rare disease,
generally with a network of satellite screening centres accessing a specialist centre [16, 20, 21]. The symptoms
of PCD are nonspecific and secondary-care physicians need guidance of whom to refer for diagnostic testing
[16]. To promote early diagnosis without overburdening specialist services, screening tools such as nasal nitric
oxide (nNO) are used, which has been proved to be an efficient screening measures [21–23]. This, however,
requires expensive equipment and trained technicians to obtain reliable measurements.
The aim of this study was to utilise easily available clinical information from a large prospective
population to produce a scoring tool to predict whether symptomatic patients have PCD: PICADAR
(PrImary CiliARy DyskinesiA Rule). We aimed to develop a tool that would be quick and easy to use by
general respiratory and ear, nose and throat specialists. PICADAR’s accuracy was externally validated in a
second PCD diagnostic centre.
Methods
Ethics
This research was approved by the National Research Ethics Service (NRES-06/Q1702/109).
Study population
Derivative group
We analysed data from 641 consecutive patients with a definitive diagnostic outcome from the University
Hospital Southampton (UHS) PCD diagnostic centre (2007–2013). A proforma was used to collect patient
data, completed by a clinician through a clinical interview prior to diagnostic testing.
External validation group
We used data from a sample of 187 patients (93 PCD-positive and 94 PCD-negative) referred for testing to
the Royal Brompton Hospital (RBH) to validate the score. An equal number of positive and negative
referrals were randomly selected from the overall population of patients referred between 1983 and 2013.
Using a similar protocol to UHS, a clinical history proforma was completed before diagnostic testing.
Diagnostic testing
The diagnostic criteria used in the UK (UHS and RBH) have previously been described in detail in
JACKSON et al. [24] and LUCAS and LEIGH [17]. In brief, a positive diagnosis is usually based on a typical
clinical history with at least two abnormal diagnostic tests (“hallmark” transmission electron microscopy
(TEM), “hallmark” ciliary beat pattern (CBP), nNO ⩽30 nL·min−1). Occasionally patients with a strong
history (e.g. sibling with PCD, “full” clinical phenotype (e.g. neonatal respiratory distress at term followed
by daily wet cough, persistent rhinitis and glue ear)), are diagnosed based on either “hallmark” TEM or
repeated high-speed video microscopy analysis (HSVMA) consistent with PCD. CBP was only considered
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positive if the pattern was typical of PCD rather than secondary ciliary dyskinesia either from two
brushing biopsies or from one brushing biopsy with reanalysis following air–liquid interface culture.
Clinical data
Data was collected on sex, date of birth, age at assessment and ethnicity. Neonatal data collected included
admittance to a special care babies unit, neonatal respiratory support, neonatal rhinitis or chest symptoms.
Data on the presence of situs abnormalities, congenital cardiac defect, chronic (>3 months) cough, rhinitis,
sinusitis, ear problems, history of pneumonia and bronchiectasis was collated. Family history of PCD,
bronchiectasis, hearing problems, asthma and consanguinity were included. Data on clinical history was
coded as yes=0, no=1 or missing=99. For the adult population, subfertility was recorded if the patient had
difficultly conceiving but had children, used in vitro fertilisation or if they stated they were never able to
conceive.
Model development
Potential predictors were restricted to information readily available in a nonspecialist setting. From the
derivation group, 27 potential variables were identified. Two-tailed parametric (t-test) or nonparametric
(Mann–Whitney) tests, Chi-squared test or Fisher’s exact test (as appropriate) were used to compare the
characteristics of positive and negative referrals.
Logistic regression analysis was used to develop a simplified practical prediction tool. First, potential
predictors were entered into the model individually using forward step-wise methods. This allowed us to
identify and select the significant predictors for PCD and assess their influence on a positive PCD
diagnosis. Sensitivity, specificity and overall accuracy (the weighted average of the models sensitivity and
specific) from selected significant predictors were interpreted [25].
Model performance
The model’s ability to discriminate between those with and without PCD was assessed by plotting the
receiver operating characteristic (ROC) curve and calculating the area under the ROC curve (AUC).
Discrimination was considered moderate if AUC 0.6–0.8 and good if AUC >0.8 [26]. The Hosmer–
Lemeshow goodness-of-fit-test was used to assess the calibration of the model, i.e. how well the predicted
probabilities agreed with the prevalence of the outcome in patient subgroups. A Hosmer–Lemeshow
goodness-of-fit-test [27] result of <0.05 indicates that the predicted probabilities and the actual outcome
agree poorly [28]. Subjects with missing data were excluded on a case-wise basis; however, to confirm the
model’s accuracy, multiple imputation was used to check for any biases that can occur in complete case
analysis along with a substantial loss of power and precision [29, 30].
Clinical prediction tool
The best model from the logistic regression allowed for the calculation of a diagnostic predictive tool
(PICADAR) to estimate the probability of a positive PCD diagnosis based on total score. The score for each
predictor corresponds to their regression coefficient rounded to the nearest integer. A ROC curve was plotted
to assess the predictive performance of PICADAR for comparison with the original model. Each score has a
corresponding accuracy (i.e. sensitivity and specificity) of predicting a positive or negative diagnosis.
Validation in external population
The discriminative ability of the scores in the validation population was assessed using ROC curve analysis.
All analyses were performed by using SPSS Statistics for Windows version 21.0 (IBM, Armonk, NY, USA).
Results
Study population
Of 641 consecutive participants in the derivation group, 75 (12%) were diagnosed with PCD and 566
(88%) had a negative diagnosis. Median (range) age at assessment was 9 (0–79) years and 44% of patients
were male.
The validation group was selected to include similar numbers of positive and negative diagnoses. The
participants were younger than the derivation group; they were also more likely to be non-white and from
a consanguineous background, reflecting the different populations served by UHS and RBH (table 1).
Clinical and family characteristics
Both PCD-positive and PCD-negative groups had a high prevalence of a persistent daily wet cough
throughout life (PCD-positive 93.3%, PCD-negative 85.1%, p=0.069). PCD-positive patients were more
likely to report neonatal problems requiring admittance to a neonatal unit (61.3%, 13.6%, p<0.001),
neonatal rhinitis (26.6%, 6.5%, p<0.001) and neonatal chest symptoms (e.g. wet cough, tachypnoea, oxygen
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requirement) (74.6%, 17.1%, p<0.001). Symptoms were higher among the PCD-positive group for
persistent perennial rhinitis (81.3%, 57.4%, p<0.001), serous otitis media (glue ear) (57.3%, 19.2%,
p<0.001) and hearing loss (49.3%, 15.9%, p<0.001). Situs abnormalities (44.0%, 3.9%, p<0.001) and
congenital cardiac defects (8.0%, 1.7%, p=0.001) were also more common in the PCD-positive group.
Fertility data was available for 152 referrals, with a significantly higher percentage reporting subfertility in
the PCD-positive group (90%, 18.4%, p<0.001). Family history of PCD in siblings (24%, 1.6%, p<0.001) or
in other family members (5.3%, 1.1%, p=0.012) was significantly higher among the PCD-positive group.
Consanguinity (16.0%, 1.4%, p<0.001) was more common in PCD-positive group. Clinical characteristics
of the derivation group are summarised in table 2 and of the validation group in online supplementary
table E1.
Development of PICADAR score
Of the 27 binary variables considered for selection, the best logistic regression model included seven
significant predictors. In order of importance (based on their corresponding odds ratio) these predictors
were situs inversus, birth at full term, neonatal chest symptoms, admission to a neonatal unit, congenital
cardiac defect, rhinitis, and ear and hearing symptoms (table 3). Similar results were found when multiple
imputation was applied (online supplementary table E2). The overall accuracy of this model was 90%, and
the sensitivity and specificity were 71% and 94%, respectively. The discriminant ability (AUC) of this
model was 0.92 (figure 1). The Hosmer–Lemeshow test showed good agreement between the predicted
probabilities and the actual outcome (p=0.64).
PICADAR (figure 2) was designed as an easily scored predictive tool based on the seven-variable-predictor
model. The presence of each clinical factor contributed to the total score following adjustment of its
regression coefficient values to an integer between 1 and 4. This adjustment had little effect on
discriminative ability (model AUC 0.92, PICADAR AUC 0.91) (figure 1).
The likelihood of a patient having PCD can be estimated by comparing their score to the probability curve
(figure 3) or cut-offs could be used. The highest combined sensitivity and specificity (0.90 and 0.75,
respectively) was at the cut-off value of 5 points (table 4). The maximum PICADAR score was 14. This
corresponded to a 99.80% probability of having PCD, a score ⩾10 had a probability of 92.6% and a score
⩾5 had a probability of 11.10% (figure 3 and online supplementary table E3). In the UHS derivation
group, of the PCD-positive, 6.0% had scores ⩽5, 58.0% had scores 6–9 and 36.0% had scores ⩾10. In the
PCD-negative group, 79.4% had scores ⩽5, 20.2% had scores 6–9 and only 0.4% had scores ⩾10 (table 5).
Validation of the PICADAR score
Validation of PICADAR used data from an independent set of 93 randomly selected PCD-positive patients
and 94 PCD-negative patients from RBH. Data for all PICADAR predictors were available in 157 (84%)
out of 187 of the validation group, all of whom were <18 years of age. The remaining 30 were excluded
due to missing symptom data. Positive cases accounted for 79 (50%) of the population, 79 (50%) were
male; mean age at assessment was 4 years. Scores in the validation group ranged from 0 to 14 (mean±SD
5.9±3.3). The mean±SD PICADAR score was higher in the PCD-positive group (PCD-positive 7.9±2.8,
TABLE 1 Demographical characteristics of the two study populations: the derivation group and the validation group#
Derivation group Validation group p-value
Total PCD-positive PCD-negative Total PCD-positive PCD-negative
Subjects 641 75 566 157 80 77
Age at assessment years 9 (0–79) 6 (0–67) 9 (0–79) 3 (0–18) 6 (0–17) 2 (0–12) <0.001
Male 283 (44) 34 (45) 249 (44) 78 (50) 38 (48) 40 (52) 0.211
Gestational age months 39±2.6 39.6±1.6 38.9±2.7 39±2.3 39±2.0 39±2.5 0.332
Pre-term 87 (14) 7 (9) 80 (14) 17 (11) 7 (9) 10 (13) 0.357
Siblings with PCD 27 (4) 18 (24) 9 (2) 27 (17) 24 (30) 3 (4) <0.001
Other family with PCD 10 (2) 4 (5) 6 (1) 8 (5) 7 (9) 1 (1) 0.007
Consanguinity 20 (3) 12 (16) 8 (1) 38 (24) 35 (44) 3 (4) <0.001
Ethnicity
White 482 (75) 57 (76) 425 (75) 90 (57) 31 (39) 59 (77) <0.001
Other 55 (9) 17 (23) 38 (7) 57 (36) 39 (49) 18 (23) <0.001
Not stated 104 (16) 1 (1) 103 (18) 10 (7) 10 (12) 0 (0) 0.002
Data are presented as n, median (range), mean±SD or n (%), unless otherwise stated. PCD: primary ciliary dyskinesia. #: missing values not presented.
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PCD-negative 3.8±2.3; p<0.01) and distribution of the scores differed between groups (online
supplementary figure E1). ROC curve analysis confirmed the performance of the score with AUC 0.87
(95% CI 0.81–0.94) (figure 4). In the validation group, 18.7% of the PCD-positive group had a score ⩽5,
53.3% had a score 6–9 and 29.1% had a score ⩾10. For the PCD-negative group, 75.6% has a score ⩽5,
20.5% had a score of 6–9 and 3.8% had a score ⩾10 (table 5).
A second predictive tool, PICADAR+S, which includes the variable “siblings with PCD” was developed
and validated for patients with one of more siblings. When validated, this tool was also shown to
discriminate between positive and negative referrals (AUC 0.94, 95% CI 0.90–0.97) (see online
supplementary material for full description).
TABLE 2 Clinical symptom characteristics of the derivation group
Total PCD-positive PCD-negative Odds ratio (95% CI) p-value
Subjects 641 75 566
Neonatal symptoms
Neonatal respiratory support 72 (11.2) 31 (41.3) 41 (7.2) 9.77 (5.53–17.26) <0.001
Neonatal chest symptoms 153 (23.0) 56 (74.6) 97 (17.1) 13.56 (7.60–24.11) <0.001
Neonatal rhinitis 57 (8.9) 20 (26.6) 37 (6.5) 5.53 (2.99–10.23) <0.001
Respiratory symptoms
Persistent daily wet cough 552 (86.1) 70 (93.3) 482 (85.1) 2.38 (0.93–6.07) 0.069
Recurrent wheeze 254 (39.6) 36 (48.0) 218 (38.5) 1.39 (0.86–2.26) 0.176
Previous pneumonia 227 (35.4) 31 (41.3) 196 (34.6) 1.14 (0.69–1.88) 0.585
Bronchiectasis 202 (31.5) 22 (29.3) 180 (31.8) 0.94 (0.54–1.61) 0.83
Upper airway and ear symptoms
Perennial persistent rhinitis 386 (60.2) 61 (81.3) 325 (57.4) 3.20 (1.75–5.86) <0.001
Chronic sinusitis 159 (24.8) 21 (28.0) 138 (24.3) 1.19 (0.69–2.05) 0.52
Hearing loss 127 (19.8) 37 (49.3) 90 (15.9) 5.90 (3.52–9.98) <0.001
Chronic acute otitis media 165 (25.7) 25 (33.3) 140 (24.7) 1.41 (0.85–2.32) 0.117
Serous otitis media 152 (23.7) 43 (57.3) 109 (19.2) 3.24 (2.11–4.96) <0.001
Chronic ear perforation 59 (9.2) 9 (12.0) 50 (8.8) 5.9 (3.52–9.98) 0.398
Ear surgery 105 (16.3) 24 (32.0) 81 (14.3) 2.81 (1.64–2.83) <0.001
Other clinical characteristics
Neonatal unit 123 (19.2) 46 (61.3) 77 (13.6) 11.13 (6.46– 19.17) <0.001
Situs abnormality 55 (8.5) 33 (44.0) 22 (3.9) 17.19 (9.18–32.19) <0.001
Congenital cardiac defect 16 (2.5) 6 (8.0) 10 (1.7) 4.75 (1.81–12.48) 0.001
Hydrocephalus 7 (1.1) 1 (1.3) 6 (1.0) 1.14 (0.13–9.61) 0.903
Developmental delay# 43 (6.7) 8 (10.6) 35 (6.2) 1.68 (0.75–3.82) 0.197
Family history of disease
PCD in siblings 27 (4.2) 18 (24.0) 9 (1.6) 19.23 (8.24–44.87) <0.001
PCD in extended family 10 (1.5) 4 (5.3) 6 (1.1) 5.22 (1.44–18.98) 0.012
Asthma 206 (32.1) 12 (16.0) 194 (34.2) 0.35 (0.18–0.67) 0.002
Bronchiectasis 28 (4.3) 3 (4.0) 25 (4.4) 0.99 (0.29–3.40) 0.998
Otitis media 65 (10.1) 5 (6.6) 60 (10.6) 0.69 (0.26–1.80) 0.456
Subfertility¶ 36 (23.6) 10 (90) 26 (18.4) 44.23 (5.42–360.91) <0.001
Data are presented as n or n (%), unless otherwise stated. PCD: primary ciliary dyskinesia. #: developmental delay includes those who present
with gross motor delay, social delay or language delay; ¶: subfertility is based on a total of 152 referrals (positive referrals n=11, negative
referrals n=141).
TABLE 3 Factors for the prediction of primary ciliary dyskinesia selected by step-wise logistic regression
Regression coefficient Odds ratio (95% CI) p-value Simplified regression coefficient tool#
Situs inversus 3.54 34.48 (11.6–101.8) <0.001 4
Gestational age (full term) 2.20 9.06 (2.9–27.4) <0.001 2
Neonatal chest symptoms 1.91 6.79 (2.7–16.7) <0.001 2
Neonatal unit 1.90 6.70 (2.7–16.3) <0.001 2
Congenital cardiac defect 1.57 4.83 (1.1–22.2) 0.043 2
Rhinitis 1.22 3.40 (1.2–8.9) 0.013 1
Ear and hearing symptoms 0.95 2.59 (1.2–5.8) 0.021 1
#: regression coefficients of the main model are rounded to the nearest integer.
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Discussion
Statement of principal findings
We have developed an easy-to-use predictive score for determining the likelihood of an individual having
a diagnosis of PCD. The score accurately predicts a positive or negative test result in patients with daily
lower respiratory tract symptoms throughout life. PICADAR was developed and validated in patients
referred to specialist diagnostic centres; at this stage we would not aim for it to be used in primary care,
but anticipate that it could be used by respiratory centres to guide referral to specialist PCD centres.
PICADAR should raise awareness of symptoms associated with PCD, and stimulate discussion and
research to further refine the tool. PCD centres could use PICADAR to identify patients who should be
investigated further following inconclusive or equivocal PCD tests. In resource limited countries with no
diagnostic facilities the tool could be used to attach a PCD-likelihood to the patients; this is important for
international research registries and metacohorts.
There is no gold standard test for PCD, and testing is restricted to centres with the infrastructure and
expertise to analyse and interpret HSVMA or TEM images and genotype data [17, 20, 31].
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PICADAR
Best model
FIGURE 1 PICADAR: receiver
operating characteristic (ROC) curves
for the best prediction model (area
under the ROC curve (AUC) 0.92, 95%
CI 0.87–0.95) and the predication tool
(AUC 0.91, 95% CI 0.87–0.95) in the
derivation group.
PICADAR
Does the patient have a daily wet cough that started in 
early childhood?
Yes – complete PICADAR
No – STOP. PICADAR is not designed for 
patients without a wet cough
1. Was the patient born pre-term or full term? Term 2
2. Did the patient experience chest symptoms in the
 neonatal period (e.g. tachypnoea, cough, pneumonia)?
Yes 2
3. Was the patient admitted to a neonatal unit? Yes 2
4. Does the patient have a situs abnormality (situs  
 inversus or heterotaxy)?
Yes 4
7. Does the patient experience chronic ear or hearing  
 symptoms (e.g. glue ear, serous otitis media, hearing
 loss, ear perforation)?
Yes
Total score =
1
5. Does the patient have a congenital heart defect? Yes 2
6. Does the patient have persistent perennial rhinitis? Yes 1
FIGURE 2 PICADAR is a predictive score with seven simple questions to predict the likelihood of having
primary ciliary dyskinesia (PCD). It can be used in any patients with chronic respiratory symptoms starting in
early childhood. The total score is calculated and the individual probability of having PCD diagnosis can be
estimated from the probability curve shown in figure 3.
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Measurement of nNO provides a good screening tool [21, 23] to differentiate PCD-positive and non-PCD
in patients with symptoms. In the study population which contributed to the development of PICADAR,
we previously reported in JACKSON et al. [24] that a cut-off of 30 nL·min−1 was both sensitive (0.91, 95% CI
0.76–0.98) and specific (0.96, 95% CI 0.93–0.98); of 301 consecutive referrals for diagnostic testing
including nNO, 31 (91%) out of 34 of PCD-positive patients had low nNO (true positive), 10 (3%) out of
267 of PCD-negative patients had low nNO (false positive) and 3/34 (9%) of PCD-positives had nNO
>30 nL·min−1 (false negative). However, the equipment for measuring nNO is not widely available outside
specialist centres and needs trained technicians to obtain reliable readings. We designed PICADAR for use
outside specialist diagnostic centres. Our data suggests similar accuracy in comparison with nNO, e.g. a
cut-off score of ⩾5 using PICADAR had 90% sensitivity and 75% specificity to differentiate PCD-positive
and PCD-negative patients in the derivation group, and had 86% sensitivity and 73% specificity in the
validation group. If patients with a score ⩽4 had not proceeded to further testing, 167 (70.2%) and 57
(73.1%) negative patients would have avoided formal testing at the diagnostic centres; however, two (4.0%)
positive patients in the derivation group and 11 (13.9%) in the validation group would have been missed
(table 5). The tool therefore should not be used in isolation when deciding who to refer. We believe that
promotion of the tool is likely to raise awareness of the most common symptoms associated with PCD.
Although PICADAR will “miss” some patients when used in isolation, since diagnosis is currently
commonly missed due to lack of physician awareness, widespread use of PICADAR would inevitably
increase the number of actual diagnoses.
Strengths and limitations of the study
PICADAR comprises seven predictive variables including full-term gestational age, admittance to a
neonatal unit, neonatal chest symptoms, persistent perennial rhinitis, chronic ear and hearing symptoms,
TABLE 4 Performance measures including sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) of the PICADAR prediction tool for different cut-off values
calculated from the derivation group and the validation group
Cut-off score Derivation group Validation group
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
0 >0.99 <0.01 0.12 >0.99 <0.01 0.51 0.00
1 >0.99 0.01 0.12 1.0
2 >0.99 0.04 0.12 1.0 >0.99 0.01 0.51 1.00
3 0.97 0.20 0.14 0.98 0.99 0.35 0.61 0.97
4 0.97 0.48 0.20 0.99 0.93 0.63 0.72 0.90
5 0.90 0.75 0.32 0.98 0.86 0.73 0.77 0.83
6 0.89 0.83 0.41 0.98 0.81 0.76 0.78 0.79
7 0.76 0.94 0.63 0.97 0.73 0.89 0.79 0.79
8 0.63 0.96 0.68 0.95 0.53 0.90 0.85 0.65
9 0.34 0.99 0.82 0.92 0.35 0.96 0.90 0.59
10 0.31 >0.99 0.80 0.92 0.29 0.96 0.88 0.57
11 0.19 >0.99 0.72 0.90 0.25 0.99 0.96 0.56
12 0.13 >0.99 1.0 0.90 0.13 0.99 0.93 0.52
13 0.01 >0.99 1.0 0.88 0.05 >0.99 1.00 0.50
14 <0.01 >0.99 0.88 0.01 >0.99 1.00 0.49
TABLE 5 The distribution of scores (⩽5, 6–9 and ⩾10) in primary ciliary dyskinesia (PCD)
positive and PCD-negative participants using PICADAR in the derivation group (n=288) and in
the validation group (n=157) (only children <18 years included)
Derivation group Validation group
PCD-positive PCD-negative PCD-positive PCD-negative
Subjects 50 238 79 78
⩽5 3 (6.0) 189 (79.4) 15 (18.7) 59 (75.6)
6–9 29 (58.0) 48 (20.2) 42 (53.3) 16 (20.5)
⩾10 18 (36.0) 1 (0.4) 22 (28.0) 3 (3.8)
Data are presented as n or n (%).
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situs abnormalities, and presence of a cardiac defect; such items are easily ascertained and quick to
compute in any clinical setting. We did not specify cardiac defects associated with laterality defects within
the score because we want PICADAR to be used by nonspecialists. PICADAR was derived in a specialist
PCD centre (UHS) and validated externally in another centre (RBH). Although these two diagnostic
centres are both situated in Southern England, they have different demographic populations in terms of
ethnicity, consanguinity and age at assessment. Good discriminant ability was maintained when used in
the validation group with AUC 0.87. The process of developing a clinical prediction rule includes four
stages before ever being implemented in routine practice (derivation, internal validation, external
validation and impact analysis). If an external validation is done directly in another setting, internal
validation is not necessary. Therefore, as of now, we have completed all three of the requested stages of the
rule development. Once these results are published, further validations can be done in other countries and
settings, by other investigators, so that they can provide additional evidence for its validity for further
implementation in practice [32].
PICADAR was developed in a large clinically relevant population. Consecutive patients with a diagnostic
outcome were included. Patients had been referred based on symptoms and/or family history. Diagnosis
was based on a combination of tests including nNO measurements, HSVMA to assess ciliary function and
TEM to assess ciliary ultrastructure [16, 18]. A detailed clinical proforma was completed by health
professionals before diagnostic testing was started, thus reducing bias.
Using PICADAR, patients with a score ⩾10 had a >90% probability of testing positive for PCD. Those
with a score ⩾5 had a >11% chance of being diagnosed PCD-positive (figure 3 and online supplementary
table E3). We believe that this guidance will support appropriate referrals of patients for specialist testing,
particularly where patients are geographically remote from a diagnostic centre. Clinicians using the score
need to be aware that individuals with low risk scores might still have PCD (table 5).
It should be noted that persistent wet cough is not included in the score because virtually all positive and
negative referrals had chronic cough; therefore, the score is for use in patients with chronic cough as a
precondition.
A potential limitation is that a significant amount of data was missing for some variables. For example, a
large proportion of the adult population did not know their gestational age and none of the children
would yet know their fertility status. Complete case analysis was used to deal with missing data; however,
this can lead to bias. To overcome this obstacle, multiple imputation was used to replace missing values
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FIGURE 3 PICADAR: probability curve. Once the total PICADAR score is calculated from figure 2, the
individual probability of having a primary ciliary dyskinesia diagnosis is estimated from the probability curve.
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within the model’s significant variables [29, 30]. The pooled result obtained from five imputed datasets
showed the best model is accurate (online supplementary table E2). Importantly, it must also be
emphasised that PICADAR was developed using a population already referred for diagnostic testing. It was
developed with the aim of identifying appropriate patients for referral from secondary care and will now
require validation in this setting. Finally, patients with equivocal results were excluded from the derivation
and validation populations. This may artificially improve the tool’s performance; however, good
discrimination was found when the tool was validated in a second diagnostic centre.
Future research
The scores were derived using combined data from adults and children, but we expect that separate scores
for adults and children might further improve accuracy. We therefore propose further research in large
cohorts of children and adults to derive separate scoring systems. PICADAR includes a number of
predictors based in early life, including gestational age and neonatal chest symptoms, that may be difficult
to recall in adulthood. Similarly, subfertility was more common in the PCD-positive group and is likely to
be a strong predictor for adult diagnoses. While the derivation group consisted of a wide range of age
groups, the majority of referrals in the external validation group were children. Furthermore, the scores
were developed and validated in UK specialist diagnostic centres, but referrals originate from nonspecialist
services, and therefore future validation will be needed in referral centres and in centres outside of the UK.
Conclusions
PICADAR provides the first validated tool to aid appropriate referral of patients for diagnostic testing. It
was designed to be easily applied in a nonspecialist setting to determine which patients with chronic chest
symptoms require PCD diagnostic testing. PICADAR is a simple cost-effective score suitable for use in all
clinical settings. The tools are now available for validation in a variety of clinical settings.
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